Pages that link to "Q1898104"
Jump to navigation
Jump to search
The following pages link to myeloproliferative disorders (Q1898104):
Displayed 50 items.
- leukemia (Q29496) (← links)
- anagrelide (Q408163) (← links)
- myelodysplastic syndrome (Q954625) (← links)
- Nick Kamen (Q958683) (← links)
- chronic neutrophilic leukemia (Q1088057) (← links)
- JAK2 mutation (Q1676512) (← links)
- Edgar Robles (Q2066217) (← links)
- dacrocytosis (Q3011657) (← links)
- Mohammad Nouri (Q4026253) (← links)
- Krishna Kumari (Q6437449) (← links)
- Category:Myeloid neoplasia (Q7214339) (← links)
- sodium phenylbutyrate (Q7553358) (← links)
- Zaōnishiki Toshimasa (Q8066327) (← links)
- myeloid neoplasm (Q18553734) (← links)
- myeloproliferative neoplasm (Q18555039) (← links)
- Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders (Q24657681) (← links)
- Evolving Therapeutic Strategies for the Classic Philadelphia-Negative Myeloproliferative Neoplasms (Q26766319) (← links)
- The Hematopoietic Niche in Myeloproliferative Neoplasms (Q26773192) (← links)
- Circulating Cytokine Levels as Markers of Inflammation in Philadelphia Negative Myeloproliferative Neoplasms: Diagnostic and Prognostic Interest (Q26777398) (← links)
- HSP90 and HSP70: Implication in Inflammation Processes and Therapeutic Approaches for Myeloproliferative Neoplasms (Q26778548) (← links)
- Cytokine Regulation of Microenvironmental Cells in Myeloproliferative Neoplasms (Q26778929) (← links)
- The Hen or the Egg: Inflammatory Aspects of Murine MPN Models (Q26778931) (← links)
- The Role of Reactive Oxygen Species in Myelofibrosis and Related Neoplasms (Q26779929) (← links)
- Inflammation as a Driver of Clonal Evolution in Myeloproliferative Neoplasm (Q26779936) (← links)
- Impact of Inflammation on Myeloproliferative Neoplasm Symptom Development (Q26779947) (← links)
- Pathogenesis of Myeloproliferative Neoplasms: Role and Mechanisms of Chronic Inflammation (Q26779960) (← links)
- Pulmonary hypertension in patients with chronic myeloproliferative disorders (Q26795658) (← links)
- Myeloid malignancies: mutations, models and management (Q27000577) (← links)
- Discovery of 1-amino-5H-pyrido[4,3-b]indol-4-carboxamide inhibitors of Janus kinase 2 (JAK2) for the treatment of myeloproliferative disorders (Q27674404) (← links)
- Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1 (Q27687464) (← links)
- Novel pyrrole carboxamide inhibitors of JAK2 as potential treatment of myeloproliferative disorders (Q27700213) (← links)
- Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders (Q27851398) (← links)
- Monitoring Minimal Residual Disease in the Myeloproliferative Neoplasms: Current Applications and Emerging Approaches (Q28076096) (← links)
- Chronic myeloproliferative disorders (Q28166225) (← links)
- Anagrelide for thrombocytosis in myeloproliferative disorders: a prospective study to assess efficacy and adverse event profile (Q28171087) (← links)
- Myeloproliferative syndromes. Current opinions from the European Hematology Association Working Group on Myeloproliferative Disorders (Q28182280) (← links)
- Hematologic aspects of liver transplantation for Budd-Chiari syndrome with special reference to myeloproliferative disorders (Q28194251) (← links)
- Myeloproliferative disorders with translocations of chromosome 5q31-35: role of the platelet-derived growth factor receptor Beta (Q28210908) (← links)
- Use of whole blood platelet lumi-aggregometry to optimize anti-platelet therapy in patients with chronic myeloproliferative disorders (Q28219426) (← links)
- Molecular pathogenesis of Philadelphia chromosome negative myeloproliferative disorders (Q28295823) (← links)
- Mutant Cbl proteins as oncogenic drivers in myeloproliferative disorders (Q28307750) (← links)
- JAK2 V617F (Q28429317) (← links)
- Mouse models of myeloproliferative neoplasms: JAK of all grades (Q28744478) (← links)
- Jakavi (Q29006050) (← links)
- GM-CSF Autoantibody-positive Pulmonary Alveolar Proteinosis with Simultaneous Myeloproliferative Neoplasm (Q29248620) (← links)
- A gain-of-function mutation of JAK2 in myeloproliferative disorders (Q29618851) (← links)
- Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders (Q29618853) (← links)
- Management of the myeloproliferative disorders : distinguishing data from dogma (Q30937966) (← links)
- Anagrelide in the treatment of essential thrombocythemia (ET) and other myeloproliferative disorders with thrombocythemia based on data from patient register in the CR (Q31044107) (← links)
- Aberrant expression of transforming growth factor beta-1 (TGF beta-1) per se does not discriminate fibrotic from non-fibrotic chronic myeloproliferative disorders (Q31149409) (← links)